Search Results
Your search for all items matches 34003 pages
Showing 701 - 750Esophageal Cancer: Neoadjuvant Triplet or Doublet Chemotherapy, With or Without Radiotherapy
As reported in The Lancet by Ken Kato, MD, and colleagues, the Japanese phase III JCOG1109 NExT trial showed that neoadjuvant triplet chemotherapy was associated with superior overall survival vs doublet chemotherapy among previously untreated patients with locally advanced esophageal squamous cell ...
Lorlatinib vs Crizotinib in Previously Untreated Advanced ALK-Positive NSCLC
As reported in the Journal of Clinical Oncology by Benjamin J. Solomon, MBBS, PhD, and colleagues, analysis of 5-year outcomes in the phase III CROWN trial showed that median progression-free survival had not been reached in previously untreated patients receiving lorlatinib vs a median of 9.1...
Previously Untreated Metastatic Pancreatic Cancer: CD40 Agonist Plus mFOLFIRINOX
In a European phase Ib/II study (OPTIMIZE-1) reported in The Lancet Oncology, Jean-Luc Van Laethem, MD, and colleagues found that the combination of the CD40 agonist antibody mitazalimab with mFOLFIRINOX (modified fluorouracil, leucovorin, oxaliplatin, and irinotecan) showed activity in previously...
Carboplatin-Induced Nausea and Vomiting: Addition of Olanzapine to Triple Antiemetic Therapy
In a Japanese phase III trial reported in the Journal of Clinical Oncology, Inui et al found that the addition of olanzapine to triple antiemetic therapy did not improve the prevention of carboplatin-induced vomiting in patients with thoracic cancers who had received no prior chemotherapy; however, ...
Radioligand Therapy May Improve Radiographic Progression–Free Survival in Taxane-Naive Patients With Advanced Prostate Cancer
Lutetium (Lu)-177–PSMA-617 radioligand therapy may offer a statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with taxane-naive metastatic castration-resistant prostate cancer, according to findings presented by Herrmann et al at the 2024...
Can FAP-Targeted Radioligand Therapy Benefit Patients With Advanced Sarcomas?
Fibroblast activation protein (FAP)-targeted radioligand therapy may be safe and effective in patients with progressive metastatic tumors, particularly advanced sarcomas, according to new findings presented by Lanzafame et al at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI)...
FAPI PET/CT May Improve Staging in Newly Diagnosed Breast Cancer
Researchers have found that fibroblast activation protein inhibitor (FAPI) positron-emission tomography/computed tomography (PET/CT) may offer more accurate staging in patients with newly diagnosed breast cancer than fluorine (F)-18–labeled fluorodeoxyglucose (FDG) PET/CT, according to new findings ...
Efficacy of Adjuvant Everolimus Plus Endocrine Therapy in High-Risk, Hormone Receptor–Positive, HER2-Negative Breast Cancer
As reported in the Journal of Clinical Oncology by Mariana Chavez-MacGregor, MD, MSc, FASCO, and colleagues, the phase III SWOG S1207 trial showed no significant benefit in invasive disease–free survival with adjuvant endocrine therapy plus 1 year of everolimus vs 1 year of placebo in patients with ...
FDA Approves Blinatumomab as Consolidation for CD19-Positive, Ph-Negative B-Cell Precursor ALL
On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved blinatumomab (Blincyto) for adult and pediatric patients aged 1 month and older with CD19-positive, Philadelphia chromosome (Ph)-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of...
FDA Approves Two Immunochemotherapy Combinations for Endometrial Cancer
On June 17, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with carboplatin and paclitaxel followed by single-agent pembrolizumab for adult patients with primary advanced or recurrent endometrial carcinoma; on June 14, the agency approved durvalumab...
Chelating Agent May Reduce Toxicity Associated With PSMA Radiopharmaceutical Therapy
A novel chelator may significantly reduce off-target toxicity in prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy, according to new findings presented by Ho et al at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting (Abstract 242340). Background...
Pretargeted Dual-Isotope Radionuclide Therapy in Colorectal Cancer
A combination of alpha- and beta-radionuclide therapy may be feasible, tolerable, and effective in colorectal cancer, according to preclinical findings presented by Rinne et al at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting (Abstract 241498). The new approach...
Using a Novel AI Tool for Cancer Detection on Whole-Body PET/CT Scans
A novel artificial intelligence (AI) tool may accurately detect six different types of cancers on whole-body positron-emission tomography/computed tomography (PET/CT) scans and automatically quantify tumor burden to assess patient risk, treatment response, and survival, according to new findings...
Previously Treated Metastatic Colorectal Cancer: Lenvatinib/Pembrolizumab vs Standard of Care
As reported in the Journal of Clinical Oncology by Akihito Kawazoe, MD, and colleagues, the final analysis of the phase III LEAP-017 trial showed no significant overall survival benefit with lenvatinib plus pembrolizumab vs the standard of care in previously treated patients with mismatch...
Lenalidomide-Exposed Relapsed or Refractory Multiple Myeloma: BPd vs PVd
As reported at the 2024 ASCO Annual Meeting (Abstract LBA105) and in The New England Journal of Medicine by Meletios Dimopoulos, MD, and colleagues, an interim analysis from the phase III DREAMM-8 trial has shown significantly improved progression-free survival with belantamab mafodotin-blmf,...
Advanced Neuroendocrine Tumors: Adding Lu-177 Dotatate to Standard First-Line Therapy
As reported in The Lancet by Simron Singh, MD, MPH, FRCPC, and colleagues, primary results of the international, multicenter, randomized phase III NETTER-2 study have shown significantly improved progression-free survival with the addition of the radioligand lutetium-177 dotatate (Lu-177 dotatate)...
Stage IIIC High-Grade Serous Ovarian Cancer After Progression on Platinum-Based Therapy and PARP Inhibitor
This is Part 3 of Overcoming Platinum Resistance in Ovarian Cancer: New Strategies and Novel Targets, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Kathleen Moore, Katherine Fuh, and Bhavana Pothuri discuss the treatment of...
Stage IIIC High-Grade Serous Ovarian Cancer With Disease Progression After Platinum-Based Therapy
This is Part 2 of Overcoming Platinum Resistance in Ovarian Cancer: New Strategies and Novel Targets, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Kathleen Moore, Katherine Fuh, and Bhavana Pothuri discuss the treatment of...
Study Documents Decline in Reimbursements for Breast Cancer Surgery From 2003 to 2023
Over the past 20 years, Medicare reimbursements for 10 breast cancer surgical procedures rose by 22%, but inflation rose three times as much—by 69%. Compared with the financial picture had rates kept pace with inflation, the result is an estimated aggregate loss of more than $100 million for breast ...
Stage IV High-Grade Endometrioid Ovarian Cancer After Progression on Platinum-Based Therapy
This is Part 1 of Overcoming Platinum Resistance in Ovarian Cancer: New Strategies and Novel Targets, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Kathleen Moore, Katherine Fuh, and Bhavana Pothuri discuss the treatment of...
Mobile Monitoring System May Improve Detection of Ethylene Oxide in Louisiana’s ‘Cancer Alley’
Measuring ethylene oxide levels using mobile optical instruments in Louisiana’s southeastern corridor may help to improve cancer risk assessments, according to a recent study published by Robinson et al in Environmental Science & Technology. Background Louisiana’s southeastern corridor is...
FDA Grants Accelerated Approval to Repotrectinib for NTRK Fusion–Positive Solid Tumors
On June 13, the U.S. Food and Drug Administration (FDA) granted accelerated approval to repotrectinib (Augtyro) for adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or...
Relapsed or Refractory JMML: Study Evaluates Trametinib
Juvenile myelomonocytic leukemia (JMML) is a rare and aggressive hematologic malignancy affecting young children predominately under the age of 4. The disease is caused by mutations that increase RAS signaling output. While about 50% of patients with JMML are cured after undergoing hematopoietic...
Dendritic Cell Therapy in Pleural Mesothelioma
As reported in The Lancet Oncology by Aerts et al, the phase II/III DENIM trial showed no overall survival benefit with a treatment comprising dendritic cells loaded with allogeneic tumor cell lysate (called MesoPher) plus best supportive care vs best supportive care alone as maintenance therapy in ...
Previously Treated Metastatic NSCLC: Sacituzumab Govitecan vs Docetaxel
As reported in the Journal of Clinical Oncology by Luis G. Paz-Ares, MD, PhD, and colleagues, the phase III EVOKE-01 trial has shown a numeric but not statistically significant improvement in overall survival with sacituzumab govitecan-hziy vs docetaxel in patients with metastatic non–small cell...
V. Craig Jordan, PhD, a Founding Father of Targeted Therapy in Cancer, Dies at Age 76
Craig Jordan, CMG, OBE, PhD, DSc, FMedSci, a pioneering scientist whose innovative work in breast cancer research has saved countless lives and will continue to impact the field for generations to come, died on June 9, according to a news release from The University of Texas MD Anderson Cancer...
Can Positive Psychology Influence Outcomes in Hematopoietic Stem Cell Transplantation Recipients?
A novel positive psychology approach may help improve stress, fatigue, physical function, and quality of life in patients with hematologic malignancies who undergo hematopoietic stem cell transplantation, according to a new study published by Amonoo et al in JNCCN–Journal of the National...
Drug Resistance in Melanoma-Related Leptomeningeal Disease
Researchers uncovered potential mechanisms driving drug resistance in patients with melanoma and leptomeningeal disease, according to a recent study published by Alhaddad et al in Cell Reports Medicine. Background Leptomeningeal disease is a rare and often lethal complication experienced by about...
FDA Approves Selpercatinib for RET Fusion–Positive Thyroid Cancer
On June 12, the U.S. Food and Drug Administration (FDA) granted traditional approval to selpercatinib (Retevmo) for adult and pediatric patients aged 2 years and older with advanced or metastatic RET fusion–positive thyroid cancer who require systemic therapy and whose disease is radioactive...
How Often Do Patients With Cancer Face Barriers When Attempting to Access Care?
Many patients with cancer encounter significant barriers to the receipt of care, according to a recent study published by Chen et al in JAMA Network Open. Background When attempting to access cancer care, patients often must go through several different levels of communication both before their...
Lung Cancer Screening May Improve Early Detection, Survival in U.S. Veterans
Investigators have found that U.S. veterans who underwent lung cancer screening prior to diagnosis were potentially more likely to be diagnosed with earlier-stage disease and have a higher cure rate compared with those who did not undergo screening, according to a recent study published by Edwards...
Newly Diagnosed Patients With Multiple Myeloma Ineligible for Transplant: Addition of Isatuximab to VRd
As reported at the 2024 ASCO Annual Meeting (Abstract 7500) and in The New England Journal of Medicine by Thierry Facon, MD, and colleagues, interim analysis of the phase III IMROZ trial showed significantly improved progression-free survival with the addition of isatuximab to bortezomib,...
Cardiac Dysfunction Among Breast Cancer Survivors
In a study reported in the Journal of Clinical Oncology, Bostany et al found that the cumulative incidence of cardiac dysfunction reached 15.3% at 15 years from the start of cardiotoxic treatments in breast cancer survivors. Study Details The study involved patients at the Next Steps Breast Cancer...
Ribociclib Plus Endocrine Therapy vs Combination Chemotherapy in Premenopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer
As reported by Yen-Shen Lu, MD, PhD, and colleagues in the Journal of Clinical Oncology, final results of the phase II RIGHT Choice study indicate that ribociclib plus endocrine therapy significantly prolonged progression-free survival vs combination chemotherapy in premenopausal women with...
Lung Cancer Screening Prevalence Among Eligible U.S. Individuals
In a study reported in JAMA Internal Medicine, Bandi et al found that only 18% of eligible individuals in the United States were considered up to date—defined as undergoing screening within the past year—for recommended annual lung cancer screening in 2022. As stated by the investigators, “The U.S. ...
Novel Gamma-Delta T Cell–Based Therapy Plus Temozolomide Maintenance in Glioblastoma Multiforme
The novel therapy INB-200 in combination with concomitant temozolomide may improve survival in patients with glioblastoma multiforme, according to preliminary findings from a phase I clinical trial presented by Lobbous et al at the 2024 ASCO Annual Meeting (Abstract 2042). “For far too long, there...
Integrating Palliative Care Education Into Hematology-Oncology Fellowships
An integrated palliative care rotation for hematology-oncology fellows may improve their palliative care knowledge and skill confidence, according to findings presented by Bauman et al at the 2024 ASCO Annual Meeting (Abstract 9007). “Despite national guidelines advocating that patients with...
Claudio Cerchione, MD, PhD, on Staging Multiple Myeloma: New Findings on FDG PET/CT Scans and Whole-Body MRI
Claudio Cerchione, MD, PhD, of Italy’s Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, discusses preliminary findings from a prospective trial suggesting that by adding whole-body MRI to fludeoxyglucose-18 (FDG) PET/CT scans, clinicians may detect bone lesions earlier and more...
More on Using AI to Enhance Cancer Care
I read with interest the excellent article by Anant Madabhushi, PhD, and Jame Abraham, MD, FACP, in the May 10, 2024, issue of The ASCO Post, entitled “AI in Cancer Care: Embrace the Change.” I wanted to add information on how an available AI Cancer Mentor application (app) has become a beneficial...
Low-Risk Prostate Cancer: Disease-Free Survival With Hypofractionated vs Conventionally Fractionated Radiotherapy
As reported in the Journal of Clinical Oncology by W. Robert Lee, MD, MS, and colleagues, a 12-year analysis of the phase III NRG Oncology RTOG 0415 trial has shown continued noninferiority in terms of disease-free survival with hypofractionated radiotherapy vs conventionally fractionated...
Can Methylphenidate Be Used to Treat Fatigue in Patients With Advanced Cancer?
In a UK trial reported in the Journal of Clinical Oncology, Stone et al found that the stimulant methylphenidate did not significantly improve fatigue vs placebo in patients with advanced cancers receiving palliative care. Study Details In the double-blind multicenter study, 159 patients with...
First-Line Venetoclax Combinations in Fit Patients With CLL
As reported in The Lancet Oncology by Fürstenau et al, 4-year follow-up of the phase III GAIA/CLL13 trial showed improved progression-free survival with venetoclax/obinutuzumab and venetoclax/obinutuzumab/ibrutinib vs both chemoimmunotherapy and venetoclax/rituximab in the first-line treatment of...
Andrew Srisuwananukorn, MD, and Alexander T. Pearson, MD, PhD, on Artificial Intelligence in the Clinic: Understanding How to Use This 21st Century Tool
Andrew Srisuwananukorn, MD, of The Ohio State University, and Alexander T. Pearson, MD, PhD, of the University of Chicago, discuss the use of artificial intelligence (AI) in the clinic, its potential benefits in diagnosis and treatment, resources available to help physicians learn more about AI,...
Guideline Update Seeks to Aid Clinicians in the Selection of Systemic Treatments for Advanced Hepatocellular Carcinoma
An ASCO guideline update offers new recommendations on systemic treatment for advanced hepatocellular carcinoma (HCC), based on promising findings from several recent randomized controlled trials as well as the approval of new first- and second-line immunotherapy combinations.1 “This guideline...
FDA’s Oncology Center of Excellence Launches Project 5 in 5, a Crowdsourcing Initiative
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, the OCE’s Steven Cunningham, MD, MLA, FACS, Clinical Reviewer on the Gastrointestinal Cancers Team,...
I Am Living With Recurring Stage IV Colorectal Cancer
Despite urgings from my primary care physician to get a colonoscopy screening after I turned 50, I resisted. As a health-care provider, and someone who is tuned into changes in my body, I thought I would instinctively know if I had a serious illness. I was wrong. Even after finally relenting to at...
In Celebration of a Remarkable Life and Career in Oncology
When Jamie H. Von Roenn, MD, FASCO, graduated from high school in 1970 and enrolled at the University of Illinois in Champaign, she was determined to seek a career in special education, because she wanted to “help people through difficult situations.” Although Dr. Von Roenn ultimately decided to...
Multiple Myeloma Survivor and Advocate Shares 12-Step Program: How Not to Die of Cancer
Facing mortality can be a paralyzing experience for some people, but for others, it may ignite a passion to accelerate life. One such person is Kathy Giusti, cofounder of the Multiple Myeloma Research Foundation (MMRF), where she served as Chief Executive Officer and President for nearly 20 years....
How the Museum of Medicine and Biomedical Discovery Aims to Bring Scientific Achievements of the Past, Present, and Future to Life
Several years ago, a visit to the National Air and Space Museum in Washington, DC, so fascinated and inspired Mace L. Rothenberg, MD, FASCO, about the history of flight, he wondered why there was not a similar museum showcasing the past and present achievements in science and medicine. The result...
Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
On April 22, 2024, the interleukin-15 receptor agonist nogapendekin alfa inbakicept-pmln was approved for use with bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors.1 Supporting Efficacy Data...
